CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 12 enrolled
Drug / intervention
Degarelix +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02489357
NCT02489357N/ACompleted

A Pilot Study of MK-3475 With Cryotherapy for Men With Newly Diagnosed Oligo-metastatic Prostate Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins·interventional·Posted Jul 3, 2015·Updated Nov 12, 2021

In Brief

A clinical study evaluating Cryosurgery, Degarelix, and 2 other interventions for Stage IV Prostate Cancer. Completed, enrolled 12 participants across 1 site.

Detailed Summary

This pilot phase II trial studies the side effects and how well pembrolizumab and cryosurgery work with short term androgen ablation to treat patients with prostate cancer that has traveled from the original tumor, through the body, and formed a small number of new tumors in other parts of the body (oligo-metastatic). Cryosurgery, also known as cryoablation or cryotherapy, kills tumor cells by freezing them. The process also incites an immune response within the ablated tumor. Giving monoclonal antibodies such as pembrolizumab which enhance a systemic anti-cancer immune response, may augment the effects of cryosurgery and increase tumor killing at distant (metastatic) sites.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedJul 3, 2015
Enrollment StartDec 11, 2015
Primary CompletionNov 30, 2017
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 11.0 years ago

Interventions

Cryosurgeryprocedure

Undergo whole gland cryoablation

Degarelixdrug

Given SC

Laboratory Biomarker Analysisother

Correlative studies

Pembrolizumabbiological

Given IV